Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours

Trial Profile

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Cisplatin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Proof of concept
  • Acronyms LiPlaCis
  • Sponsors LiPlasome Pharma; Oncology Venture
  • Most Recent Events

    • 29 Sep 2017 According to an Oncology Venture media release, next report on progress of trial is expected in Q1 2018.
    • 29 Sep 2017 According to an Oncology Venture media release, 12 patients with metastatic breast cancer has been enrolled and the patient number may expand to upto 20 patient in the phase 2 part of the trial.The company has increased the inclusion from the top 20% sensitive patients to include the top 2/3 of patients.
    • 19 Sep 2017 Early results from 5 patients treated in the phase II portion of this trial published in a Medical Prognosis Institute media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top